Other languages Can-Fite BioPharma Ltd.

Equities

CANF

IL0010944739

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 06:19:08 30/06/2024 pm IST			5-day change	1st Jan Change
3.4 ^ILa	+3.03%		+3.03%	+30.77%

28/06	Can-Fite BioPharma Ltd. Announces Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Vetbiolix	CI
24/06	Can-Fite Announces Breakthrough Findings Demonstrate Namodenoson Anti-Cancer and Protective Effect Mechanism in the Liver	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Can-Fite BioPharma Ltd. Announces Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Vetbiolix	28/06
Can-Fite Announces Breakthrough Findings Demonstrate Namodenoson Anti-Cancer and Protective Effect Mechanism in the Liver	24/06
Can-Fite Biopharma Ltd. Receives IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study	10/06
Can-Fite Biopharma Ltd. Updates on Its Advanced Liver Cancer Pivotal Phase 3 Study	05/06
Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	09/05
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602	06/05
Can-Fite Biopharma Ltd. Announces Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis, Also Known as Non-Alcoholic Steatohepatitis, for the Company's Ongoing Phase IIb Clinical Study	03/04
Can-Fite Biopharma Ltd. Announces Clinical Update	28/03
Can-Fite BioPharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Can-Fite Biopharma Ltd. to Present Data from the Pancreatic and Liver Cancer Programs	11/03
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the Canadian Intellectual Property Office	28/02
Can-Fite BioPharma Ltd. Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication	30/01
Can-Fite Biopharma Ltd. Announces Results from Randomized Phase 3 Clinical Trial	29/01
Can-Fite BioPharma Ltd. Reports New Data on Namodenoson?s Anti-Obesity Mechanism of Action	20/12
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan	18/12
Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson	18/12
Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients	04/12
Can-Fite BioPharma Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/11
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon	22/11
Top Midday Gainers	22/11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Can-Fite BioPharma Ltd.

Equities

CANF

IL0010944739

Other languages

Filters